Ticker

InnovAge Holding Corp. (INNV) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

InnovAge Holding Corp. (NASDAQ: INNV - Get Free Report) traded up 8.5% on Monday after JPMorgan Chase and Co. raised their price target on the stock from $5.00 to $7.00. JPMorgan Chase and Co. currently has an underweight rating on the stock. InnovAge traded as high as $8.80 and last traded at $8.8540. 49,382 shares traded

InnovAge Holding Corp. delivers strong operational execution, driving significant revenue and margin expansion through its PACE model for elderly care. INNV's revenue rose 14.7% year-over-year, fueled by participant growth and capitation rate adjustments across established centers. Disciplined cost management and SG&A reductions have expanded center-level contribution margin to 22% and adjusted EBITDA margin to 9.2%.

Aclarion (NASDAQ: ACON - Get Free Report) and InnovAge (NASDAQ: INNV - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership. Volatility and Risk Aclarion has a beta of 1.44,

InnovAge (INNV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).